BioCentury
ARTICLE | Clinical News

Celvapan H1N1 regulatory update

October 5, 2009 7:00 AM UTC

EMEA's CHMP issued a positive opinion to grant marketing approval for Baxter's Celvapan H1N1 pandemic influenza vaccine. CHMP recommended a 2-dose vaccination schedule, with a 3-week interval, for adults, including pregnant women, and children ages 6 months and older. The company said it has already delivered the Vero cell-based, whole virion, inactivated swine influenza A (H1N1) vaccine to several countries, including the U.K. and Ireland, for use in their national vaccination programs. ...